LD2-3
LD2-3 is a cytotoxic compound derived from Exatecan (HY-13631), designed to be conjugated with anti-FGFR2b or anti-CEA antibodies to form intact antibody-drug conjugate (ADC) molecules. LD2-3 exhibits a remarkable bystander killing effect: it not only effectively kills FGFR2b-positive tumor cells, but also eliminates surrounding FGFR2b-negative cells in co-culture and mixed tumor xenograft models, thereby inducing complete tumor regression. LD2-3 can be used for anti-tumor research in relevant fields such as gastric cancer and lung cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3040077-52-6
- Fòrmula: C59H74FN11O18
- Peso molecular:1244.28
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas ADC Payloads
MoreVer todos los productos específicos de isoformas Topoisomerase
More
Actividad biológica
Descripciòn
IC50 & Target
|
Topoisomerase I |
In Vitro
BGA3457 (anti-FGFR2b antibody BGAh9179 conjugated to LD2-3) (34.75 ng/mL) exhibits potent bystander killing activity against FGFR2b-negative HuTu-80-NanoLuc cells cocultured with FGFR2b-positive SNU-16 cells, with an IC50 of 34.75 ng/mL and a maximum killing potency of 90.74%[1].
BGA3457 and BGA9823 (anti-FGFR2b antibodies conjugated to LD2-3) exhibit comparable internalization activity in SNU16, SNU601-h2b, H1048-h2b, and HSC-39 cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
LD2-3 (10 mg/kg; i.v.; single dose), as part of immunoconjugate BGA9823, induces complete regression of mixed FGFR2b-positive/negative gastric tumors in BALB/c nude mice[1].
LD2-3 (1-10 mg/kg; i.v.; single dose), as part of immunoconjugates BGA3457 and BGA9823, inhibits tumor growth in a FGFR2b-expressing gastric cancer xenograft model in BALB/c nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6 to 8 weeks old)[1]
-
Dosage:10 mg/kg (delivered as part of immunoconjugate BGA3457)
-
Administration:i.v.; single dose
-
Result:Induced complete tumor regression in both 2:1 and 5:1 HSC-39:SNU-5 co-inoculation models.
Chemical Information
-
No. CAS 3040077-52-6
-
Peso molecular 1244.28
-
Fòrmula C59H74FN11O18
-
SMILES
O=C(C=CC1=O)N1CC(NCCC(N[C@@H](CCC(NC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)CC(N)=O)=O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(NCOCC(C)(C)C(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LD2-3 Related Classifications
HY-178238 Related Classifications
Powered by Bioz